Drug pricing order hits few, helps many

Roughly 28% of the R70,000-crore Indian pharmaceutical market will soon come under a benign market-based price regulation as against 18% under the existing opaque cost-based control regime. This will lead to modest revenue losses (up to 6% by an industry estimate) at several pharmaceutical companies, but others, especially the smaller ones, might even benefit.

Read Full Story>>